Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;42(4):406-414.
doi: 10.3343/alm.2022.42.4.406.

Prognostic Utility of Procalcitonin, Presepsin, and the VACO Index for Predicting 30-day Mortality in Hospitalized COVID-19 Patients

Affiliations

Prognostic Utility of Procalcitonin, Presepsin, and the VACO Index for Predicting 30-day Mortality in Hospitalized COVID-19 Patients

Mikyoung Park et al. Ann Lab Med. .

Abstract

Background: Biomarkers and clinical indices have been investigated for predicting mortality in patients with coronavirus disease (COVID-19). We explored the prognostic utility of procalcitonin (PCT), presepsin, and the Veterans Health Administration COVID-19 (VACO) index for predicting 30-day-mortality in COVID-19 patients.

Methods: In total, 54 hospitalized COVID-19 patients were enrolled. PCT and presepsin levels were measured using the Elecsys BRAHMS PCT assay (Roche Diagnostics GmbH, Mannheim, Germany) and HISCL Presepsin assay (Sysmex, Kobe, Japan), respectively. The VACO index was calculated based on age, sex, and comorbidities. PCT and presepsin levels and the VACO index were compared using ROC curve, Kaplan-Meier method, and reclassification analysis for the 30-day mortality.

Results: ROC curve analysis was used to measure PCT and presepsin levels and the VACO index to predict 30-day mortality; the optimal cut-off values were 0.138 ng/mL for PCT, 717 pg/mL for presepsin, and 12.1% for the VACO index. On Kaplan-Meier survival analysis, hazard ratios (95% confidence interval) were 15.9 (4.1-61.3) for PCT, 26.3 (6.4-108.0) for presepsin, and 6.0 (1.7-21.1) for the VACO index. On reclassification analysis, PCT and presepsin in addition to the VACO index significantly improved the prognostic value of the index.

Conclusions: This study demonstrated the prognostic utility of measuring PCT and presepsin levels and the VACO index in COVID-19 patients. The biomarkers in addition to the clinical index were more useful than the index alone for predicting clinical outcomes in COVID-19 patients.

Keywords: 30-Day mortality; COVID-19; Prediction; Presepsin; Procalcitonin; VACO index.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

None declared.

Figures

Fig. 1
Fig. 1
Flowchart for patient enrollment. Abbreviation: COVID-19, coronavirus disease.
Fig. 2
Fig. 2
ROC curve analysis of PCT, presepsin, the SOFA score, WHO disease severity, the VACO index, and multimarker approaches for predicting 30-day mortality. (A) PCT, presepsin, the SOFA score, WHO disease severity, and the VACO index. (B) Multimarker approaches using the above optimal cut-off values of PCT, presepsin, and the VACO index. Abbreviations: PCT, procalcitonin; SOFA, sequential organ failure assessment; VACO, Veterans Health Administration COVID-19; AUC, area under the ROC curve; CI, confidence interval.
Fig. 3
Fig. 3
Kaplan–Meier survival curves of PCT, presepsin, the SOFA score, WHO disease severity, and the VACO index for predicting 30-day mortality. (A) PCT. (B) Presepsin. (C) SOFA score. (D) WHO disease severity. (E) VACO index. Abbreviations: PCT, procalcitonin; SOFA, sequential organ failure assessment; VACO, Veterans Health Administration COVID-19; HR, hazard ratio; CI, confidence interval.

Similar articles

Cited by

References

    1. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020;40:351–60. doi: 10.3343/alm.2020.40.5.351. - DOI - PMC - PubMed
    1. Kim SW, Kim SM, Kim YK, Kim JY, Lee YM, Kim BO, et al. Clinical characteristics and outcomes of COVID-19 cohort patients in Daegu metropolitan city outbreak in 2020. J Korean Med Sci. 2021;36:e12. doi: 10.3346/jkms.2021.36.e12. - DOI - PMC - PubMed
    1. Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. Int J Infect Dis. 2020;98:462–6. doi: 10.1016/j.ijid.2020.07.017. - DOI - PMC - PubMed
    1. Yoo EH, Chang SH, Song DY, Lee CH, Cheong GY, Park S, et al. Comprehensive laboratory data analysis to predict the clinical severity of coronavirus disease 2019 in 1,952 patients in Daegu, Korea. Ann Lab Med. 2022;42:24–35. doi: 10.3343/alm.2022.42.1.24. - DOI - PMC - PubMed
    1. Korea Disease Control and Prevention Agency, author. Current status of COVID-19 outbreak and vaccination in Korea (6.30.) [Updated on Nov 2021]. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=....